Monday, January 27, 2020 Gene Therapy Shows Promise for Rare Immune Disease Findings from early-stage clinical trials suggest the promise of a gene therapy approach for repairing immune function in people with X-linked chronic granulomatous disease (CGD), a genetic immune deficiency characterized by susceptibility to certain bacterial and fungal infections. An international team including NIAID scientists reports results from nine gene therapy recipients, aged 2 to 27 years, today in Nature Medicine. One year after receiving the gene therapy, seven of the participants had no new CGD-related infections, and six were able to stop taking the daily prophylactic antibiotics needed to reduce risk from the life-threatening infections that can occur in people with CGD. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107